Cutting-Edge Cannabis Products On The Horizon As Biotech Co. Funds New Research
Portfolio Pulse from Jelena Martinovic
Synaptogenix, Inc. (NASDAQ:SNPX) has partnered with Cannasoul Analytics Ltd. to support research and development of pharmaceutical therapeutics. Synaptogenix has obtained a preemptive right to fund further research and commercialization of certain intellectual property, technology, and future products developed by Cannasoul and licensed from The Technion. Cannasoul has developed technology in large disease markets including leukemia, epilepsy and sleep disorders.
November 02, 2023 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Synaptogenix has partnered with Cannasoul Analytics to support R&D of pharmaceutical therapeutics. This partnership could potentially lead to the development of new products and technologies, which could positively impact Synaptogenix's future revenues and market position.
The partnership with Cannasoul Analytics could potentially lead to the development of new products and technologies, which could positively impact Synaptogenix's future revenues and market position. This is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100